Sirolimus 5mg Tablet

Sirolimus 5mg Tablet ( SiroBoon 5mg ) contains sirolimus (rapamycin), an mTOR inhibitor used to prevent organ transplant rejection and regulate abnormal immune responses. It helps suppress T-cell activity while preserving kidney function better than some traditional immunosuppressants. Used under specialist medical supervision.

What Is Sirolimus 5 mg Tablet?

Sirolimus is an immunosuppressive medicine best known for its role in organ transplantation.

When a patient receives a transplanted kidney, liver, or other organ, the immune system immediately recognizes it as foreign. Left unchecked, the body may attempt to destroy the transplanted tissue.

Sirolimus helps prevent this response.

Unlike older immunosuppressants that broadly suppress immune activity, sirolimus specifically targets the mTOR (mammalian target of rapamycin) pathway, a critical regulator of cell growth, immune activation, and cellular metabolism.

Today, sirolimus is widely recognized not only in transplant medicine but also in several emerging areas of specialty care.

Who Is Usually Prescribed Sirolimus?

Doctors commonly prescribe sirolimus for:

• Kidney transplant recipients
• Organ transplant maintenance therapy
• Lymphangioleiomyomatosis (LAM)
• Certain vascular anomalies
• Tuberous sclerosis-related conditions
• Specialist mTOR-targeted treatment protocols

Treatment requires careful monitoring of blood levels to ensure effectiveness and safety.

Why Sirolimus Is Different From Traditional Immunosuppressants

Most transplant patients are familiar with drugs such as tacrolimus or cyclosporine.

Sirolimus belongs to a different category.

Rather than targeting calcineurin pathways, it inhibits mTOR signaling, affecting immune-cell proliferation and growth.

This distinction can be clinically important.

In selected patients, sirolimus-based regimens may help preserve kidney function while providing effective immunosuppression.

Its unique mechanism is one reason sirolimus remains one of the most studied immunosuppressive agents in modern medicine.

Product Information

Attribute	Details
Generic Name	Sirolimus
Alternative Name	Rapamycin
Brand Name	Rapamune®
Strength	5 mg
Dosage Form	Tablet
Drug Class	mTOR Inhibitor
Route	Oral
Used For	Organ Transplant Rejection Prevention, LAM, mTOR Disorders

Is sirolimus the same as rapamycin?

Yes. Rapamycin is the original name of sirolimus. Both refer to the same active pharmaceutical ingredient.

What is sirolimus used for?

Sirolimus is primarily used to prevent organ transplant rejection, particularly in kidney transplant recipients. It is also used in certain rare diseases involving mTOR pathway dysregulation.

Is sirolimus a chemotherapy drug?

No. Sirolimus is classified as an immunosuppressant and mTOR inhibitor, although its pathway is also studied in cancer research.

How does sirolimus prevent transplant rejection?

It blocks the mTOR pathway, preventing activated immune cells from multiplying and attacking transplanted tissue.

Does sirolimus require blood monitoring?

Yes. Regular blood tests are often necessary to ensure therapeutic drug levels and minimize side effects.

Is sirolimus used for longevity research?

Sirolimus has attracted scientific interest in aging and longevity research because of its effects on mTOR signaling. However, such uses remain investigational and are not approved indications.

1. Do you ship Sirolimus 5 mg Tablets internationally?

Answer: Yes. International shipping is available to many countries, subject to local regulations and product availability.

2. Is this equivalent to Rapamune®?

Answer: Sirolimus contains the same active ingredient found in Rapamune® and is used for similar therapeutic purposes.

3. How is the product packaged?

Answer: Products are supplied in manufacturer-sealed pharmaceutical packaging and packed securely for international delivery.

4. How can I verify authenticity?

Answer: Verify manufacturer details, batch number, expiry date, and original packaging upon receipt.

How it works

Many immunosuppressants work by directly blocking immune-cell activation.

Sirolimus works differently.

Instead of stopping immune cells from becoming activated, it prevents them from multiplying effectively after activation.

This distinction reduces the body's ability to mount a rejection response against a transplanted organ.

By inhibiting the mTOR pathway, sirolimus may:

• Reduce organ rejection risk
• Suppress T-cell proliferation
• Improve long-term transplant outcomes
• Support certain rare disease treatments
• Reduce abnormal cellular growth signals

Its mechanism is so unique that researchers continue studying sirolimus in oncology, rare diseases, and longevity-related research.

Condition	Clinical Use
Kidney Transplantation	Prevention of organ rejection
Organ Transplant Maintenance	Long-term immunosuppression
Lymphangioleiomyomatosis (LAM)	Disease progression management
Tuberous Sclerosis Complex	Specialist-directed therapy
Vascular Malformations	Selected treatment protocols
mTOR Pathway Disorders	Targeted therapeutic use

Strength	Common Use
1 mg	Maintenance therapy
2 mg	Standard dosing protocols
5 mg	Higher-dose specialist regimens
Individualized Dosing	Based on blood level monitoring

Dosage is determined by transplant specialists and adjusted according to therapeutic drug monitoring.